Acuta Capital Partners, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Acuta Capital Partners, LLC
- $98.8 Million
- Q3 2024
A detailed history of Acuta Capital Partners, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 131,700 shares of CRNX stock, worth $7.38 Million. This represents 6.81% of its overall portfolio holdings.
Number of Shares
131,700
Previous 135,141
2.55%
Holding current value
$7.38 Million
Previous $6.05 Million
11.15%
% of portfolio
6.81%
Previous 6.52%
Shares
5 transactions
Others Institutions Holding CRNX
# of Institutions
241Shares Held
79.6MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$353 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$349 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$330 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$277 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$250 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $3.01B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...